All articles by GlobalData Healthcare

Navigating uncertainty: the future of vaccine oversight amid CDC firings

In a controversial move on 9 June 2025, US Secretary of Health and Human Services Robert F Kennedy Jr dismissed…
Alzheimer’s R&D resurgence driven by $16.8bn in acquisitions in 2025YTD

Biopharmaceutical companies developing Alzheimer’s disease innovator drugs have witnessed a flurry of acquisitions over the past few years, surging in…
London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape

Many biotechnology companies are navigating the various obstacles prevalent within the pharmaceutical industry with the implementation of artificial intelligence (AI)…
CNS innovator oligonucleotide licensing value up 339% from £2bn in 2024

Innovator oligonucleotide-based drugs targeting central nervous system (CNS) indications witnessed a 339% ($2.17bn) increase in total licensing agreement deal value…
EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL

At the 2025 Congress of the European Hematology Association (EHA 2025), held from 12 June 12 to 15 June in…

EHA 2025: Regeneron’s Lynozyfic with Amgen’s Kyprolis combo emerges for R/R MM

At the 2025 Congress of the European Hematology Association (EHA 2025), held from 12 June to 15 June in Milan,…
Myasthenia gravis market to reach $10.3bn across 7MM by 2034

The myasthenia gravis (MG) market across the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the…
Vutrisiran marks first silencer approved for ATTR-CM

Transthyretin amyloidosis (ATTR) is a protein conformational disorder caused by the build-up of transthyretin, the protein carrying thyroxine and retinol…
EyePoint advances with Duravyu Phase III trial

EyePoint has entered the final phase of development for its lead product, Duravyu, announcing the completion of patient enrolment for…
Solid tumours: CAR-T therapies’ Waterloo

CAR-Ts are revolutionising the treatment of blood cancers such as B-cell acute lymphocytic leukaemia. However, their success has not yet…